CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Collagenase Clostridium Histolyticum Single Injection Technique +1 moredrug
Likely dose
Collagenase Clostridium Histolyticum Single Injection Technique 0.07 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04236635
NCT04236635Phase 2Completed
CompareCT.gov

A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model

Endo Pharmaceuticals·interventional·Posted Jan 22, 2020·Updated Apr 12, 2022

In Brief

A Phase 2 clinical trial evaluating Collagenase Clostridium Histolyticum Single Injection Technique and Collagenase Clostridium Histolyticum Multiple Injection Technique for Characteristics of Subcutaneous Tissue. Completed, enrolled 10 participants across 2 sites.

Detailed Summary

To evaluate the histopathology of subcutaneous tissue isolated after single or multiple Collagenase Clostridium Histolyticum (CCH) injection techniques in adult female participants undergoing abdominoplasty.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCharacteristics of Subcutaneous Tissue
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJan 22, 2020
Enrollment StartDec 20, 2019
Primary CompletionSep 23, 2020
Study CompletionOct 26, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.4 years ago

Interventions

Collagenase Clostridium Histolyticum Single Injection Techniquedrug

CCH was injected subcutaneously using a single injection technique. Dose per each administration was 0.07 mg.

Collagenase Clostridium Histolyticum Multiple Injection Techniquedrug

CCH was injected subcutaneously using a multiple injection technique. Dose per each administration was 0.0653 mg.